Edition:
United Kingdom

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

8.80USD
17 Nov 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$8.80
Open
--
Day's High
--
Day's Low
--
Volume
400
Avg. Vol
103,244
52-wk High
$14.73
52-wk Low
$6.25

Chart for

About

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes... (more)

Overall

Beta: --
Market Cap(Mil.): $762.55
Shares Outstanding(Mil.): 73.68
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.24 16.44
EPS (TTM): -- -- --
ROI: -- 2.53 10.62
ROE: -- 3.17 14.20

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company's humanized anti-CTLA-4 monoclonal antibody​

10 Nov 2017

BRIEF-Aduro Biotech reports Q3 loss per share $0.33

* Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S

31 Oct 2017

BRIEF-Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD

* Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD based on proprietary neoantigen technology

27 Sep 2017

BRIEF-Aduro Biotech announces advancement of adu-s100 into global combination trial with pdr001 for the treatment of solid tumors and lymphomas

* Aduro Biotech announces advancement of ADU-S100 into global combination trial with PDR001 for the treatment of solid tumors and lymphomas

26 Sep 2017

BRIEF-HitGen and Aduro Enter Research Collaboration

* Entered into a multi-target multi-year collaboration with Aduro Biotech Inc

14 Aug 2017

BRIEF-Aduro Biotech files for resale of up to 25.41 mln shares of common stock by the selling stockholders‍​

* Aduro Biotech Inc files for resale of up to 25.41 million shares of co's common stock by the selling stockholders‍​ - sec filing Source text - http://bit.ly/2v0rE5d Further company coverage:

02 Aug 2017

BRIEF-Aduro Biotech files for mixed shelf of upto $300 mln

* Aduro Biotech Inc files for mixed shelf of upto $300 million - sec filing Source text - http://bit.ly/2w7SKYi Further company coverage:

02 Aug 2017

BRIEF-Aduro Biotech Q2 loss per share $0.27

* Aduro Biotech reports second quarter 2017 financial results

02 Aug 2017

BRIEF-Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck

* Aduro Biotech- $2.0 million milestone payment under worldwide licensing deal with merck for work supporting preparation of ind for anti-cd27 antibody​

13 Jul 2017

BRIEF-Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda

* Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda® (pembrolizumab) for the treatment of patients with previously treated malignant pleural mesothelioma Source text for Eikon: Further company coverage:

28 Jun 2017

Earnings vs. Estimates